GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals Inc (NAS:SCLN) » Definitions » Cost of Goods Sold

SciClone Pharmaceuticals (SciClone Pharmaceuticals) Cost of Goods Sold : $23.2 Mil (TTM As of Jun. 2017)


View and export this data going back to 1992. Start your Free Trial

What is SciClone Pharmaceuticals Cost of Goods Sold?

SciClone Pharmaceuticals's cost of goods sold for the three months ended in Jun. 2017 was $5.7 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Jun. 2017 was $23.2 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. SciClone Pharmaceuticals's Gross Margin % for the three months ended in Jun. 2017 was 87.3%.

Cost of Goods Sold is also directly linked to Inventory Turnover. SciClone Pharmaceuticals's Inventory Turnover for the three months ended in Jun. 2017 was 0.30.


SciClone Pharmaceuticals Cost of Goods Sold Historical Data

The historical data trend for SciClone Pharmaceuticals's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals Cost of Goods Sold Chart

SciClone Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.00 17.67 23.00 22.35 22.90

SciClone Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.71 5.58 5.79 6.17 5.65

SciClone Pharmaceuticals Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $23.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SciClone Pharmaceuticals  (NAS:SCLN) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

SciClone Pharmaceuticals's Gross Margin % for the three months ended in Jun. 2017 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(44.52 - 5.654) / 44.52
=87.3 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

SciClone Pharmaceuticals's Inventory Turnover for the three months ended in Jun. 2017 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


SciClone Pharmaceuticals Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


SciClone Pharmaceuticals (SciClone Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
SciClone Pharmaceuticals Inc is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders.
Executives
Richard J Hawkins director 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Nancy T Chang director 101 WESTCOTT, SUITE 603, HOUSTON TX 77007
Raymond Anthony Low director, officer: VP, Finance & Controller 25 SHADOW TREE CT, DANVILLE CA 94506
Wilson Wai-shun Cheung officer: CFO & Senior VP, Finance SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Robert King officer: SVP of Prod. Dev/Supply Chain 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Winnie Wing-kei Tso other: VP, Finance and Controller 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Stephanie Wong officer: VP, Finance and Controller 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Gary Titus officer: Senior VP Finance & CFO SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Farmaceutica Lda Defiante 10 percent owner RUA DOS FERREIROS,260, FUNCHAL MADEIRA S1 9000-082
Dean S Woodman director 233 MOCKINGBIRD TRAIL, PALM BEACH FL 33480